fluvoxamine + basimglurant

**fluvoxamine + basimglurant** is a combination drug comprised of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), and basimglurant (RO4917523), a small-molecule negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5). - **Fluvoxamine** inhibits serotonin reuptake, increasing serotonin levels in the brain and is indicated for obsessive-compulsive disorder and depression. - **Basimglurant** selectively modulates the mGlu5 receptor by negative allosteric inhibition, targeting glutamatergic neurotransmission pathways thought to play a role in treatment-resistant depression and fragile X syndrome. Preclinical and early clinical studies suggest basimglurant may have antidepressant and anxiolytic effects, with potential for use as an adjunct in major depressive disorder. The combination may be investigated for its effects on pharmacokinetics and CNS outcomes, but as of now, there is no approved indication for either the combination or for basimglurant monotherapy.